Medizone International, Inc.

AsepticSure™

AsepticSureGlobe1

AsepticSure™

Medizone International, Inc. is a research and development company engaged in developing its AsepticSure™ System to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures. Current research is being conducted at Medizone’s dedicated laboratories located in Innovation Park, Queen’s University in Kingston, Ontario, Canada.

It is anticipated that AsepticSure™ will be extremely cost effective and adaptable to virtually any situation anywhere and have a global reach.

January 20. 2010: Unprecedented Kill Rates Foundation for Second Patent Application and Full Scale Hospital Mockup Underway

Unprecedented Kill Rates

Medizone International announced unprecedented success in being able to predictably achieve 6 log (99.9999%) kill rates for the causative agents of Hospital Acquired Infections (HAIs) represented with AsepticSure™.

All samples tested during the third round of trials were either completely destroyed, that is no growth compared to the control samples, or so significantly reduced that the effect met the 6 log definition for sterilization.

The actual results of this series of tests indicate reductions in pathogens, commonly associated with HAIs, can reliably be achieved by AsepticSure™ as follows:

>6.5 log for C difficile

>7 log for MRSA

7 log for E-coli

6.6 log for VRE

7 log for Pseudomonas aeruginous

> 7 log for Bacillus subtilis

The sterilization of contaminated hospital spaces with a fully portable unit is now within reach without enormous expense, which will translate into greatly reduced suffering, thousands of lives saved and a dramatic cost benefit for the health care system globally.

Full Scale Mock Up

Medizone’s research has now progressed to the full-scale mock up. By introducing the same combinations and protocols to room scale testing that produced >6 log with all HAI pathogens in the laboratory, our research team is confident the results produced should coincide with what has already been achieved in the most recent round of laboratory trials. Initial results from these scale-up trials can be expected in the near future.

Second Patent Application Filed

Medizone International, Inc. further announced that a second patent application was filed which in combination with its previous patent application for AsepticSure™ filed in July of 2009. This patent application affords the Company greatly enhanced protection for both the hospital version of AsepticSure™ and the government variant intended for bio-terrorism countermeasures.

The integration of several complimentary technologies, each with their own antimicrobial effects, which in combination were shown not to be additive, but multiplicative motivated this filing.

January 5. 2010: Third Round Testing Complete

Medizone International, Inc. third round of testing and data logging for the enhanced AsepticSure™ technology is now complete. Test results achieved over the past two months now predictably demonstrate greater than 6 logs of bacterial “kill” across the full spectrum of hospital contaminants including MRSA, C difficile, E coli, Pseudomonas aeruginosa and VRE in addition to the internationally accepted surrogate for Anthrax, Bacillus subtilis.

Significantly, these results have been replicated on more than a single surface material. “This latest round of laboratory testing has confirmed beyond any reasonable doubt that our enhanced AsepticSure™ technology can reliably achieve sterilization standards for virtually any bacterial contaminant found in a hospital setting,” stated Dr. Michael Shannon, Medizone’s Director of Medical Affairs.

Medizone’s full scale prototype unit has been completed and demonstrated in “dry” runs (bacteria free) that it can reach both the charge time and saturation requirements of its design criteria. The ability to replicate the exact atmosphere of the laboratory test unit in a full sized room is considered a crucial step in achieving the same 6 log bactericidal action in hospital settings.

December 1. 2009: Testing Breaks "6 Log" Decontamination Barriers

Medizone International, Inc. announced that in tests involving proprietary AsepticSure™ technology, it continues to break "6 log" decontamination barriers, this time with two very different spore forming bacteria, Clostridium difficile and Bacillus subtilis. These results clearly establish AsepticSure™ as an extremely potent sporicidal technology.

"The implications of a 6.7 log reduction (99.99997 %) in C. difficile are indeed significant for the entire health care system,” stated Dr Michael Shannon, Director of Medical Affairs for Medizone. “However, even though our findings for Bacillus subtilis are preliminary, the potential of being able to eliminate 99.999992% (7.2 log kill) of an internationally accepted surrogate for Anthrax in 90 minutes will have national security implications."

Medizone believes that a field hardened variant of the AsepticSure™ hospital unit currently being readied for scale up testing will have wide bio defense applications internationally as it will be easily deployable in response to virtually any terrorist assault, extremely effective against a broad range of lethal pathogens, easy to manage and maintain and most importantly, it has the potential to save lives.

Medizone Reliably and Predictably Able to Break Through 6 Log Barrier with MRSA

Medizone International, Inc. (MZEI.OB) announces an ability to achieve a level of bacterial decontamination heretofore unseen in open space settings using conventional means.

Dr Michael E. Shannon, Director of Medical Affairs, Medizone International stated, "our research team has pressed hard over the last few months to systematically evaluate various decontamination options involving numerous technological approaches in combination, and to our surprise, we have managed reliably and predictably to break through the 6 log barrier with MRSA. This unexpected development will significantly expand the utility for AsepticSure™, since by definition, any bacterial reduction beyond 6 logs (99.9999%) is considered STERILIZATION.

This unique combination of technologies and protocols will now be tested on C difficile, E coli, Pseudomonas aeruginous, and VRE with the expectation that AsepticSure™ will achieve the same degree of incremental improvement over the 4 to 5 log reductions we have already demonstrated with those pathogens in earlier trials.”

Medizone International is preparing a second patent filing to cover these developments while construction and instrumentation of an expanded laboratory setting at the company’s Innovation Park, Queens University laboratory continues in preparation for full room scale-up testing of its equipment to commence in December.

Second Round Trials

Results from the second series of trials demonstrated a 5 log reduction (99.999%) in Pseudomonas Aeruginousa and a 4.4 log reduction (99.994%) in Methicillin Resistant Staph Aureus (MRSA).

AsepticSure™ Hospital Sterilization System

In parallel research conducted at BioZone Corporation, Medizone's engineering development partner, it was confirmed the AsepticSure™ hospital sterilization system can charge a room of 1,065 cubic feet to the target ozone level in less than 15 minutes, which is followed by the ozone decontamination phase. The same room can then be returned to a habitable standard (less than 0.02 ppm ozone) in 13 minutes using a separate ozone destruct technology. This confirms the start to finish time to complete the entire decontamination process can be achieved with minimal disturbance to normal hospital flow patterns.

Commercial Viability of AsepticSure™ Hospital Sterilization System

From a commercial viewpoint, the higher the "kill rate" in the shortest turn around time, the more favorably physicians and hospital administrators will view the system. Accordingly, Medizone now believes that the performance profile of its AsepticSure™ Sterilization System will exceed all the prerequisite requirements of affordability, practicability and unmatched efficacy, which will catapult it into the world market.

January 5. 2010 Update

Medizone International, Inc. third round of testing and data logging for the enhanced AsepticSure™ technology is now complete. Test results achieved over the past two months now predictably demonstrate greater than 6 logs of bacterial “kill” across the full spectrum of hospital contaminants including MRSA, C difficile, E coli, Pseudomonas aeruginosa and VRE in addition to the internationally accepted surrogate for Anthrax, Bacillus subtilis.

Significantly, these results have been replicated on more than a single surface material. “This latest round of laboratory testing has confirmed beyond any reasonable doubt that our enhanced AsepticSure™ technology can reliably achieve sterilization standards for virtually any bacterial contaminant found in a hospital setting,” stated Dr. Michael Shannon, Medizone’s Director of Medical Affairs.

Medizone’s full scale prototype unit has been completed and demonstrated in “dry” runs (bacteria free) that it can reach both the charge time and saturation requirements of its design criteria. The ability to replicate the exact atmosphere of the laboratory test unit in a full sized room is considered a crucial step in achieving the same 6 log bactericidal action in hospital settings.

December 1, 2009, Update